|
Volumn 23, Issue 2, 1994, Pages 72-80
|
Treatment strategy for disseminated langerhans cell histiocytosis
a a a a b |
Author keywords
chemotherapy; diabetes insipidus; mortality; permanent consequences; VP16
|
Indexed keywords
ETOPOSIDE;
MERCAPTOPURINE;
METHOTREXATE;
PREDNISONE;
VINBLASTINE;
ADOLESCENT;
ARTICLE;
CHILD;
COMBINATION CHEMOTHERAPY;
DIABETES INSIPIDUS;
DRUG CARCINOGENICITY;
FEMALE;
HISTIOCYTOSIS;
HISTIOCYTOSIS X;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
INFANT;
INTRAVENOUS DRUG ADMINISTRATION;
LONG TERM CARE;
MAJOR CLINICAL STUDY;
MALE;
MORTALITY;
NEWBORN;
ORAL DRUG ADMINISTRATION;
PRIORITY JOURNAL;
RECURRENCE RISK;
SURVIVAL RATE;
TREATMENT PLANNING;
6-MERCAPTOPURINE;
ADOLESCENT;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CHILD;
CHILD, PRESCHOOL;
DIABETES INSIPIDUS;
ETOPOSIDE;
FEMALE;
HISTIOCYTOSIS, LANGERHANS-CELL;
HUMAN;
INFANT;
INFANT, NEWBORN;
MALE;
METHOTREXATE;
PREDNISONE;
PROGNOSIS;
PROSPECTIVE STUDIES;
RECURRENCE;
REMISSION INDUCTION;
SEVERITY OF ILLNESS INDEX;
SUPPORT, NON-U.S. GOV'T;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
VINBLASTINE;
|
EID: 0028275643
PISSN: 00981532
EISSN: 1096911X
Source Type: Journal
DOI: 10.1002/mpo.2950230203 Document Type: Article |
Times cited : (266)
|
References (47)
|